The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1

Kidney fibrosis and fibrogenesis significantly exacerbate chronic kidney disease (CKD) progression and are essential therapeutic targets. Bortezomib (BZM) is a proteasome inhibitor used for the treatment of multiple myeloma (MM). Several studies have demonstrated that BZM attenuates renal impairment...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Zeniya, Moko, Mori, Takayasu, Yui, Naofumi, Nomura, Naohiro, Mandai, Shintaro, Isobe, Kiyoshi, Chiga, Motoko, Sohara, Eisei, Rai, Tatemitsu, Uchida, Shinichi
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5638992/
https://ncbi.nlm.nih.gov/pubmed/29026167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-13486-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky